EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Butyrate‐Mediated Upregulation of Insulin Pathway Gene Expression Suggests Potential Antidiabetic Effects

Elad Shapira iD, Irena Voinsky iD, Hana Klin, David Gurwitz iD

Drug Development Research · 2025-12 · 86 (8)

DOI: 10.1002/ddr.70203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 30.11.2025. Verfasst von Elad Shapira und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Insulin, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Butyric Acid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2D) is a major cause of morbidity in developed countries and involves insulin resistance, a failure to correctly respond to insulin. Numerous studies in rodent T2D models suggested that the short‐chain fatty acid butyrate, produced by gut microbiota species through fermentation of dietary fibers, improves T2D symptoms. Here, we explored the potential antidiabetic effects of butyrate by measuring the transcription of selected T2D‐implicated genes in human B lymphocyte‐derived lymphoblastoid cell lines (LCLs) from 17 unrelated adult healthy donors. Human LCLs were cultured with and without sodium butyrate (1 mM for 48 h), followed by RNA extraction and real‐time PCR analysis of the selected T2D‐related genes. Butyrate significantly upregulated the expression of MT2A , RRAGD, IGF1R , OXTR , and INSR , while no changes were observed in the expression of other selected genes implicated in insulin signaling. Our findings, which should be considered preliminary until demonstrated by in vivo T2D animal models, suggest that butyrate is a potential modulator of metabolic pathways relevant to insulin resistance. Future studies should explore the tentative therapeutic potential of butyrate and its upregulated genes using proteomics and metabolomics in relevant tissues of T2D animal models, possibly followed by controlled clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinHypoglycemic AgentsDiabetes Mellitus, Type 2Butyric AcidButyratesHumansUp-RegulationCell LineInsulin ResistanceSignal TransductionAdult

Stichwörter der Autor:innen

Type 2 diabetes (T2D)butyratedietary fibersgut microbiomeinsulin resistance

Substanzen

InsulinHypoglycemic AgentsButyric AcidButyrates

Autor:innen und Institutionen

  • Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Gray School of Medicine, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Elad Shapira, Irena Voinsky, David Gurwitz

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Shapira, E., Voinsky, I., Klin, H., & Gurwitz, D. (2025). Butyrate‐Mediated Upregulation of Insulin Pathway Gene Expression Suggests Potential Antidiabetic Effects. Drug Development Research, 86(8). https://doi.org/10.1002/ddr.70203

Vancouver

Shapira E, Voinsky I, Klin H, Gurwitz D. Butyrate‐Mediated Upregulation of Insulin Pathway Gene Expression Suggests Potential Antidiabetic Effects. Drug Development Research. 2025;86(8). doi:10.1002/ddr.70203

BibTeX
@article{Shapira2025,
  author = {Shapira, Elad and Voinsky, Irena and Klin, Hana and Gurwitz, David},
  title = {Butyrate‐Mediated Upregulation of Insulin Pathway Gene Expression Suggests Potential Antidiabetic Effects},
  journal = {Drug Development Research},
  year = {2025},
  volume = {86},
  number = {8},
  doi = {10.1002/ddr.70203}
}
Kostenlos starten →